Symons Julian A. 4
4 · Aligos Therapeutics, Inc. · Filed Oct 20, 2020
Insider Transaction Report
Form 4
Symons Julian A.
See Remarks
Transactions
- Conversion
Common Stock
2020-10-20+3,394→ 392,612 total - Conversion
Series B-2 Preferred Stock
2020-10-20−1,452→ 0 total→ Common Stock (1,452 underlying) - Conversion
Series A Preferred Stock
2020-10-20−13,671→ 0 total→ Common Stock (13,671 underlying) - Conversion
Common Stock
2020-10-20+13,671→ 389,218 total - Conversion
Common Stock
2020-10-20+1,452→ 394,064 total - Conversion
Series B-1 Preferred Stock
2020-10-20−3,394→ 0 total→ Common Stock (3,394 underlying)
Footnotes (1)
- [F1]Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date.